Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Huqun Li"'
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 15 (2024)
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical pr
Externí odkaz:
https://doaj.org/article/85ae7cc67ed9413bbb717cad0969bbfd
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundLorlatinib displays marked systemic and intracranial efficacy against anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). We aimed to establish the safety profile of lorlatinib based on the Food and Drug Administra
Externí odkaz:
https://doaj.org/article/911b7b7c037045ffa104eb761d542db4
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepoliz
Externí odkaz:
https://doaj.org/article/5b5e5375938b4ed8a995e04cc65e9659
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 142, Iss , Pp 112071- (2021)
Aims: c-jun N-terminal kinase (JNK) plays pivotal roles in many physiological processes, including inflammation and glucose metabolism. However, the effects of JNK on olanzapine-induced insulin resistance and the underlying mechanisms have not been f
Externí odkaz:
https://doaj.org/article/66f6995af02d4843bd726c22339c85be
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 133, Iss , Pp 110912- (2021)
Aims: The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats. Methods: Rats were randomly divided into three groups: the control (Control) group, the olanzapine (Ola) group and th
Externí odkaz:
https://doaj.org/article/0dd38c20a8ea417688ff0fdea2770c0a
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0167930 (2016)
Atypical antipsychotics such as olanzapine cause metabolic side effects leading to obesity and insulin resistance. The underlying mechanisms remain elusive. In this study we investigated the effects of chronic treatment of olanzapine on the fatty aci
Externí odkaz:
https://doaj.org/article/b41b440c31a44804bec5138d425ce066
Publikováno v:
Biomedicinepharmacotherapy = Biomedecinepharmacotherapie. 142
c-jun N-terminal kinase (JNK) plays pivotal roles in many physiological processes, including inflammation and glucose metabolism. However, the effects of JNK on olanzapine-induced insulin resistance and the underlying mechanisms have not been fully e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3878ee34e41449366684b4947a759a54
https://pubmed.ncbi.nlm.nih.gov/34449309
https://pubmed.ncbi.nlm.nih.gov/34449309
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 142, Iss, Pp 112071-(2021)
Aims c-jun N-terminal kinase (JNK) plays pivotal roles in many physiological processes, including inflammation and glucose metabolism. However, the effects of JNK on olanzapine-induced insulin resistance and the underlying mechanisms have not been fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3109bf3f22459ff43eb6ac9da1172cd7
https://doi.org/10.1016/j.biopha.2021.112071
https://doi.org/10.1016/j.biopha.2021.112071
Autor:
Yunxiang Huo, Shiyong Peng, Yahui Deng, Ni Yang, Weiyong Li, Liangyu Yu, Shihong Li, Maosheng Fang, Huqun Li, Yifan Lv, Shouqing Liu
Publikováno v:
Journal of clinical psychopharmacology. 39(3)
Background Olanzapine, a commonly used second-generation antipsychotic, causes severe metabolic adverse effects, such as elevated blood glucose and insulin resistance (IR). Previous studies have proposed that overexpression of CD36, GGPPS, PTP-1B, GR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1d649cfac4ec481595213f9d9718b37
https://pubmed.ncbi.nlm.nih.gov/30946280
https://pubmed.ncbi.nlm.nih.gov/30946280
Autor:
Liangyu Yu, Weiyong Li, Taohua Sun, Shiyong Peng, Yahui Deng, Shihong Li, Zhongjian Zhang, Huqun Li, Yunxiang Huo, Ni Yang, Maosheng Fang, Yifan Lv, Ying Chen, Shouqing Liu
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Olanzapine is a second-generation anti-psychotic drug used to prevent neuroinflammation in patients with schizophrenia. However, the long-term administration of olanzapine leads to insulin resistance (IR); the mechanisms of this effect remains poorly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a235f9e0988a0b4cdd3eacdb52b9186
https://doi.org/10.1038/s41598-018-36930-y
https://doi.org/10.1038/s41598-018-36930-y